Meyka Pro banner
Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited (RGC) Stock Overview

Explore Regencell Bioscience Holdings Limited’s financial performance, market position, analyst ratings, and future outlook.

RGCNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$6.005
$0.99(19.62%)
U.S. Market is Open · 15:52

Regencell Bioscience Holdings Limited (RGC)

Meyka AI Score

Z

Key Financials

Market Cap2.5B
P/E Ratio-357.04
EPS (TTM)$-0.01
ROE-2.32%
Fundamental Analysis

AI Price Forecasts

1 Month$5.42
3 Months$0.00
1 Year Target$26.57

RGC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Regencell Bioscience Holdings Limited (RGC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 35.49, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $26.57.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -357.04 and a market capitalization of 2.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.59%
5-Day Change
-8.93%
1-Month Change
-51.47%
3-Month Change
-81.85%
6-Month Change
-79.03%
Year-to-Date (YTD) Change
-75.71%
1-Year Change
-64.58%
3-Year Change
868.99%
5-Year Change
1990.59%
All-Time (Max) Change
1745.69%

Contact Information

852 2155 0823
First Commercial Building, Causeway Bay, NaN, KY1-1107

Company Facts

100 Employees
IPO DateJul 16, 2021
CountryHK
Actively Trading

Frequently Asked Questions